Key facts
- It has raised $504.9M; the latest was PE Growth/Expansion ($450.0M) in May 2024.
- Notable investors include Tata Group, Trilantic North America, MRM Capital, Cycad Group.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for SOFIE
- ·The full record, as it builds
Funding rounds
No funding rounds for SOFIE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SOFIE
Developer of molecular imaging probes and devices designed to offer radiopharmaceutical products for Vivo research purposes. The company's devices help physicians to search throughout the body for tumors that will respond to drugs that target dCK, enabling caregivers to get access to theragnostic and innovative technologies for personalized healthcare and for more patient-specific treatment selection.
- Sector
- Healthcare
- HQ
- Dulles, VA, United States
- Founded
- 2008
- Employees
- 320
- Website
- sofie.com/
- Ownership
- Privately Held (backing)
SOFIE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SOFIE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SOFIE in its N-PORT filings yet. We sweep new filings monthly.